274 related articles for article (PubMed ID: 21711341)
61. Extracellular matrix and dermal nerve growth factor dysregulation in prurigo nodularis compared to atopic dermatitis.
Deng J; Parthasarathy V; Marani M; Bordeaux Z; Lee K; Trinh C; Cornman HL; Kambala A; Pritchard T; Chen S; Sutaria N; Oladipo OO; Kwatra MM; Alphonse MP; Kwatra SG
Front Med (Lausanne); 2022; 9():1022889. PubMed ID: 36619628
[TBL] [Abstract][Full Text] [Related]
62. Interleukin 36 expression in psoriasis variants and other dermatologic diseases with psoriasis-like histopathologic features.
Aquino TM; Calvarido MG; North JP
J Cutan Pathol; 2022 Feb; 49(2):123-132. PubMed ID: 34346097
[TBL] [Abstract][Full Text] [Related]
63. There is no functional small-fibre neuropathy in prurigo nodularis despite neuroanatomical alterations.
Pereira MP; Pogatzki-Zahn E; Snels C; Vu TH; Üçeyler N; Loser K; Sommer C; Evers AWM; van Laarhoven AIM; Agelopoulos K; Ständer S
Exp Dermatol; 2017 Oct; 26(10):969-971. PubMed ID: 28370394
[TBL] [Abstract][Full Text] [Related]
64. Methyl-β-cyclodextrin concurs with interleukin (IL)-4, IL-13 and IL-25 to induce alterations reminiscent of atopic dermatitis in reconstructed human epidermis.
De Vuyst É; Giltaire S; Lambert de Rouvroit C; Malaisse J; Mound A; Bourtembourg M; Poumay Y; Nikkels AF; Chrétien A; Salmon M
Exp Dermatol; 2018 Apr; 27(4):435-437. PubMed ID: 27304612
[No Abstract] [Full Text] [Related]
65. Prurigo nodularis: a benign dermatosis derived from a persistent pruritus.
Vaidya DC; Schwartz RA
Acta Dermatovenerol Croat; 2008; 16(1):38-44. PubMed ID: 18358109
[TBL] [Abstract][Full Text] [Related]
66. [Pathogenesis of prurigo nodularis].
Raap U; Günther C
Hautarzt; 2014 Aug; 65(8):691-6. PubMed ID: 25113327
[TBL] [Abstract][Full Text] [Related]
67. Prurigo Nodularis Is Characterized by Systemic and Cutaneous T Helper 22 Immune Polarization.
Belzberg M; Alphonse MP; Brown I; Williams KA; Khanna R; Ho B; Wongvibulsin S; Pritchard T; Roh YS; Sutaria N; Choi J; Jedrych J; Johnston AD; Sarkar K; Vasavda C; Meixiong J; Dillen C; Bondesgaard K; Paolini JF; Chen W; Corcoran D; Devos N; Kwatra MM; Chien AL; Archer NK; Garza LA; Dong X; Kang S; Kwatra SG
J Invest Dermatol; 2021 Sep; 141(9):2208-2218.e14. PubMed ID: 33771530
[TBL] [Abstract][Full Text] [Related]
68. Severe allergic dysregulation due to a gain of function mutation in the transcription factor STAT6.
Baris S; Benamar M; Chen Q; Catak MC; Martínez-Blanco M; Wang M; Fong J; Massaad MJ; Sefer AP; Kara A; Babayeva R; Eltan SB; Yucelten AD; Bozkurtlar E; Cinel L; Karakoc-Aydiner E; Zheng Y; Wu H; Ozen A; Schmitz-Abe K; Chatila TA
J Allergy Clin Immunol; 2023 Jul; 152(1):182-194.e7. PubMed ID: 36758835
[TBL] [Abstract][Full Text] [Related]
69. Increased IL-31 expression in serum and tissue protein in prurigo nodularis.
Chaowattanapanit S; Wongjirattikarn R; Chaisuriya N; Ungarreevittaya P; Poosekeaw P; Winaikosol K; Choonhakarn C; Julanon N; Salao K
Ther Adv Chronic Dis; 2022; 13():20406223221112561. PubMed ID: 35875833
[TBL] [Abstract][Full Text] [Related]
70. Association between Prurigo Nodularis and Etiologies of Peripheral Neuropathy: Suggesting a Role for Neural Dysregulation in Pathogenesis.
Hughes JM; Woo TE; Belzberg M; Khanna R; Williams KA; Kwatra MM; Hassan S; Kwatra SG
Medicines (Basel); 2020 Jan; 7(1):. PubMed ID: 31936197
[No Abstract] [Full Text] [Related]
71. Cytokine regulation during epidermal differentiation and barrier formation.
Tsuchisaka A; Furumura M; Hashimoto T
J Invest Dermatol; 2014 May; 134(5):1194-1196. PubMed ID: 24732332
[TBL] [Abstract][Full Text] [Related]
72. Myeloid dendritic cells are increased in the lesional skin and associated with pruritus in patients with prurigo nodularis.
Liu T; Chu Y; Li S; Wang Y; Zhong X; Fang H; Qiao J
MedComm (2020); 2023 Feb; 4(1):e204. PubMed ID: 36789100
[TBL] [Abstract][Full Text] [Related]
73. The pathogenesis of Prurigo nodularis--'Super-Itch' in exploration.
Zeidler C; Ständer S
Eur J Pain; 2016 Jan; 20(1):37-40. PubMed ID: 26416433
[TBL] [Abstract][Full Text] [Related]
74. STAT6 and phosphorylated STAT6 are differentially expressed in lymphomas.
Karpathiou G; Ferrand E; Papoudou-Bai A; Camy F; Honeyman F; Dumollard JM; Peoc'h M
Pathol Res Pract; 2022 Jan; 229():153697. PubMed ID: 34839096
[TBL] [Abstract][Full Text] [Related]
75. A Prospective Study Examining the Effect of Selected Topical and Systemic Drugs on Pruritus Grading System Score and STAT 6 Expression in Patients of Prurigo Nodularis.
Agrawal D; Sardana K; Mathachan SR; Bhardwaj M; Ahuja A; Jain S
Indian J Dermatol; 2021; 66(6):638-644. PubMed ID: 35283533
[TBL] [Abstract][Full Text] [Related]
76. Interleukin-31 and Pruritic Skin.
Furue M; Furue M
J Clin Med; 2021 Apr; 10(9):. PubMed ID: 33924978
[TBL] [Abstract][Full Text] [Related]
77. Prurigo as a symptom of atopic and non-atopic diseases: aetiological survey in a consecutive cohort of 108 patients.
Iking A; Grundmann S; Chatzigeorgakidis E; Phan NQ; Klein D; Ständer S
J Eur Acad Dermatol Venereol; 2013 May; 27(5):550-7. PubMed ID: 22364653
[TBL] [Abstract][Full Text] [Related]
78. Fixed drug eruptions: evidence for a cytokine-mediated process.
Smoller BR; Luster AD; Krane JF; Krueger J; Gray MH; McNutt NS; Hsu A; Gottlieb AB
J Cutan Pathol; 1991 Feb; 18(1):13-9. PubMed ID: 1827131
[TBL] [Abstract][Full Text] [Related]
79. Simultaneous treatment of Samter triad and prurigo nodularis with dupilumab.
Bloomstein JD; Hawkes JE
JAAD Case Rep; 2021 Dec; 18():20-22. PubMed ID: 34778501
[No Abstract] [Full Text] [Related]
80. Prurigo Nodularis: A Review of IL-31RA Blockade and Other Potential Treatments.
Bewley A; Homey B; Pink A
Dermatol Ther (Heidelb); 2022 Sep; 12(9):2039-2048. PubMed ID: 35986886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
